M. Schlemmer - Concepedia

Author

M. Schlemmer

Ludwig-Maximilians-Universität München

Also Known As

M Schlemmer, M. Schlemmer, M. Schlemmer, Marcus Schlemmer, Schlemmer M., Schlemmer, M.

103

Publications

5.5K

Citations

H-Index

Concepts

All Affiliations

Ludwig-Maximilians-Universität München Helios Hospital Bad Saarow Heidelberg University University Hospital Münster Krankenhaus Nordwest

About

M. Schlemmer is an author at Ludwig-Maximilians-Universität München specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	22	2.7K
2	Gastroenterology	8	8	758
3	Health Sciences	6	6	292
4	Cell Biology	1	1	32
5	Clinical Nutrition	1	1	39

M. Schlemmer

Publications

4.8K

Citations

H-Index

Page 1

	Year	Citations
One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, JAMA	2012	955
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours Maria Dêbiec‐Rychter, Raf Sciot, Axel Le Cesne, European Journal of Cancer OncologyGastrointestinal OncologyMedicineKit MutationsDose Selection	2006	893
Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mg John Zalcberg, Jaap Verweij, Paolo G. Casali, European Journal of Cancer Daily Imatinib DoseGastrointestinal OncologyMedicineGastroenterologyColorectal Cancer	2005	373
Initial and Late Resistance to Imatinib in Advanced Gastrointestinal Stromal Tumors Are Predicted by Different Prognostic Factors: A European Organisation for Research and Treatment of Cancer–Italian Sarcoma Group–Australasian Gastrointestinal Trials Group Study M. van Glabbeke, Jaap Verweij, Paolo G. Casali, Journal of Clinical Oncology Imatinib DoseEuropean OrganisationDifferent Prognostic FactorsGastrointestinal OncologyMalignant Disease	2005	279
Paclitaxel in patients with advanced angiosarcomas of soft tissue: A retrospective study of the EORTC soft tissue and bone sarcoma group M. Schlemmer, Peter Reichardt, Jaap Verweij, European Journal of Cancer Surgical OncologyTumoral PathologyBone Sarcoma GroupMedicinePathology	2008	233
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Journal of Clinical Oncology	2015	225
Gastrointestinal stromal tumors: ESMO Clinical Recommendations for diagnosis, treatment and follow-up Paolo G. Casali, L.M. Jost, Peter Reichardt, Annals of Oncology Surgical OncologyGastrointestinal OncologyMedicineGastroenterologyGastrointestinal Stromal Tumors	2008	187
Effect of <i>KIT</i> and <i>PDGFRA</i> Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib Heikki Joensuu, Eva Wardelmann, Harri Sihto, JAMA Oncology	2017	185
Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib Katherine A. Janeway, Karen Albritton, Annick D. Van den Abbeele, Pediatric Blood & Cancer	2009	158
Impact of human herpesvirus‐6 after haematopoietic stem cell transplantation Marcus Hentrich, Daniel Oruzio, Gundula Jäger, British Journal of Haematology	2004	151

Page 1